Recently, AstraZeneca has established a new health-tech business called Evinova. The venture will leverage the company’s expertise in clinical trial design and study delivery to offer solutions at scale to trial sponsors, clinical research organizations, care teams, and patients.
Evinova’s offerings will include advanced data collection techniques and machine learning algorithms to support study design teams. The goal is to streamline the development of new medications, bring care closer to home for patients, and reduce the burden on healthcare systems. The company has announced significant partnerships with clinical research organizations Parexel and Fortrea to expand the reach of Evinova’s digital health solutions to a broader customer base.
Pascal Soriot, CEO of AstraZeneca, expressed confidence in Evinova’s potential to significantly impact patient care, healthcare transformation, and carbon emissions reduction. The company also highlighted the expected growth of the digital health market, projecting it to be worth more than $900 billion by 2032.
For more information about Evinova and its offerings, please contact Michael Susin at michael.susin@wsj.com.